Website
Ratings & Metrics
Joint Costs
National Psoriasis Foundation's rating was adjusted for Joint Costs. If you are a donor who considers direct mail, telemarketing, and other Joint Cost solicitations to be true charitable programs, the below efficiency ratios, which were not adjusted for joint costs, may better reflect your goals.
| Program % | Cost to Raise $100 |
|---|---|
| 74% | $19 |
Financial Documents
| Entity | Document Type | Tax ID |
|---|---|---|
| National Psoriasis Foundation | IRS Form 990 | 93-0571472 |
| National Psoriasis Foundation | Audited Financial Statements | 93-0571472 |
|
Entity: National Psoriasis Foundation Document Type: IRS Form 990 Tax ID: 93-0571472 |
|
Entity: National Psoriasis Foundation Document Type: Audited Financial Statements Tax ID: 93-0571472 |
Governance & Transparency
Top Salaries
| Name | Title | Compensation | |
|---|---|---|---|
| 1 | Randy Beranek | President/CEO | $587,406 |
| 2 | Leah Howard | Chief Operating Officer | $329,342 |
| 3 | Stacy Bell | Chief Scientific & Medical Officer | $245,115 |
|
1 Name: Randy Beranek Title: President/CEO Compensation: $587,406 |
|
2 Name: Leah Howard Title: Chief Operating Officer Compensation: $329,342 |
|
3 Name: Stacy Bell Title: Chief Scientific & Medical Officer Compensation: $245,115 |
Analysts' Notes
According to the National Psoriasis Foundation audit of June 30, 2021 (Note 2 re: Refundable Advances): "The Paycheck Protection Program (PPP) loan guaranteed by the Small Business Administration (SBA) is accounted for as a conditional advance and accrues interest at 1%. The advance may be forgiven partially or in its entirety if certain conditions are met, including incurrence of allowable qualifying expenses (mostly personnel and occupancy costs) and acceptance and approval of the forgiveness application by the lender. Upon satisfaction of the conditions, the advance will be recognized as revenue. The Foundation received a PPP loan during the year ended June 30, 2020 and satisfied the conditions during 2021 and $825,046 was recognized as grant revenue. The Foundation received a second PPP loan of $1,030,637 during the year ended June 20, 2021 [sic]. The total amount was forgiven subsequent to year end." |
According to the National Psoriasis Foundation audit of June 30, 2021 (Note 15, Concentrations and Credit Risk): "Investment securities are exposed to various risks such as interest rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the [audited] statement of financial position." |
According to the National Psoriasis Foundation (NPF) tax filing for the fiscal year ended June 30, 2021, NPF reports re: Compensation, Supplemental Information (IRS Form 990, Schedule J, Part III): Regarding: (1) the payment or accrual of any compensation to officers, directors, trustees, key employees and highest compensated employees contingent on the revenues of the organization; (2) the payment or accrual of any compensation to officers, directors, trustees, key employees and highest compensated employees contingent on the net earnings of the organization; and (3) any nonfixed payments to officers, directors, trustees, key employees and highest compensated employees (Schedule J, Part I, lines 5a, 6a, & 7): "The executive team performance-based bonus portion of the compensation was based on a combination of the employee's performance against their individual objectives (50%), the NPF meeting its annual revenue target (25%) and the NPF meeting its net surplus target (25%). All staff are included in the incentive plan at 1% based on revenue and 1% based on net surplus."
|